Unraveling Non-coding RNAs in Breast Cancer: Mechanistic Insights and Therapeutic Potential

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2024 Dec 28

PMID 39730979

Authors

Muqtada Shaikh

Gaurav Doshi

Affiliations

Soon will be listed here.

Abstract

Breast cancer remains a leading global health challenge requiring innovative, therapeutic strategies to improve patient outcomes. This review explores the pivotal roles of non-coding RNAs (ncRNAs), including long non-coding RNA, micro RNA, and circular RNA, in breast cancer biology. We highlight how these molecules regulate critical signaling pathways, influence tumor microenvironments, and contribute to treatment resistance. Our findings underscore the potential of ncRNAs as biomarkers for early diagnosis and as treatment targets for personalized treatment strategies. To pave the way for innovative cancer management approaches, we investigate the complex interactions of ncRNAs and their impact on tumor progression. This comprehensive review enhances our understanding of breast cancer biology while emphasizing the translational significance of ncRNA research in developing effective treatment strategies. Additional research and clinical studies are required to confirm the diagnostic and medicinal value of ncRNAs in breast cancer. Investigating the complex networks of ncRNA interactions and their links to other biological pathways can lead to the discovery of new treatment targets. Furthermore, leveraging advanced technologies, such as machine learning and multi-omics methods, will be critical in improving our understanding of ncRNAs biomarkers and translating these insights into impactful clinical applications.

Citing Articles

Editorial: Non-coding RNAs in breast cancer, volume II.

Zhang W, Kataoka N, Guan X Front Oncol. 2025; 15:1561190.

PMID: 40008003 PMC: 11851079. DOI: 10.3389/fonc.2025.1561190.

References

Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M . Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022; 66:15-23. PMC: 9465273. DOI: 10.1016/j.breast.2022.08.010. View

Masoud V, Pages G . Targeted therapies in breast cancer: New challenges to fight against resistance. World J Clin Oncol. 2017; 8(2):120-134. PMC: 5385433. DOI: 10.5306/wjco.v8.i2.120. View

Yardim-Akaydin S, Karahalil B, Nacak Baytas S . New therapy strategies in the management of breast cancer. Drug Discov Today. 2022; 27(6):1755-1762. DOI: 10.1016/j.drudis.2022.03.014. View

Caldon C, Daly R, Sutherland R, Musgrove E . Cell cycle control in breast cancer cells. J Cell Biochem. 2005; 97(2):261-74. DOI: 10.1002/jcb.20690. View

Youness R, El-Tayebi H, Assal R, Hosny K, Esmat G, Abdelaziz A . MicroRNA-486-5p enhances hepatocellular carcinoma tumor suppression through repression of IGF-1R and its downstream mTOR, STAT3 and c-Myc. Oncol Lett. 2016; 12(4):2567-2573. PMC: 5038225. DOI: 10.3892/ol.2016.4914. View

Kansara S, Singh A, Badal A, Rani R, Baligar P, Garg M . The emerging regulatory roles of non-coding RNAs associated with glucose metabolism in breast cancer. Semin Cancer Biol. 2023; 95:1-12. DOI: 10.1016/j.semcancer.2023.06.007. View

Morceau F, Chateauvieux S, Gaigneaux A, Dicato M, Diederich M . Long and short non-coding RNAs as regulators of hematopoietic differentiation. Int J Mol Sci. 2013; 14(7):14744-70. PMC: 3742271. DOI: 10.3390/ijms140714744. View

Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K . Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol. 2009; 79(6):817-24. DOI: 10.1016/j.bcp.2009.10.017. View

Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak V, Chekhun V . Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther. 2008; 7(7):2152-9. DOI: 10.1158/1535-7163.MCT-08-0021. View

10.

Liu Z, Sall A, Yang D . MicroRNA: An emerging therapeutic target and intervention tool. Int J Mol Sci. 2009; 9(6):978-999. PMC: 2658779. DOI: 10.3390/ijms9060978. View

11.

Ho T, Zhou N, Huang J, Koirala P, Xu M, Fung R . Targeting non-coding RNAs with the CRISPR/Cas9 system in human cell lines. Nucleic Acids Res. 2014; 43(3):e17. PMC: 4330338. DOI: 10.1093/nar/gku1198. View

12.

Wang D, Yin G . Non-coding RNAs mediated inflammation in breast cancers. Semin Cell Dev Biol. 2023; 154(Pt C):215-220. DOI: 10.1016/j.semcdb.2023.05.007. View

13.

Kung J, Colognori D, Lee J . Long noncoding RNAs: past, present, and future. Genetics. 2013; 193(3):651-69. PMC: 3583990. DOI: 10.1534/genetics.112.146704. View

14.

Xu S, Kong D, Chen Q, Ping Y, Pang D . Oncogenic long noncoding RNA landscape in breast cancer. Mol Cancer. 2017; 16(1):129. PMC: 5525255. DOI: 10.1186/s12943-017-0696-6. View

15.

Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H . The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012; 22(9):1775-89. PMC: 3431493. DOI: 10.1101/gr.132159.111. View

16.

Lv M, Xu P, Wu Y, Huang L, Li W, Lv S . LncRNAs as new biomarkers to differentiate triple negative breast cancer from non-triple negative breast cancer. Oncotarget. 2016; 7(11):13047-59. PMC: 4914340. DOI: 10.18632/oncotarget.7509. View

17.

Zhao L, Bi M, Zhang H, Shi M . Downregulation of NEAT1 Suppresses Cell Proliferation, Migration, and Invasion in NSCLC Via Sponging miR-153-3p. Cancer Biother Radiopharm. 2020; 35(5):362-370. DOI: 10.1089/cbr.2019.3119. View

18.

Cong S, Di X, Li R, Cao Y, Jin X, Tian C . RBM10 regulates alternative splicing of lncRNA Neat1 to inhibit the invasion and metastasis of NSCLC. Cancer Cell Int. 2022; 22(1):338. PMC: 9636673. DOI: 10.1186/s12935-022-02758-w. View

19.

Lei C, Li S, Fan Y, Hua L, Pan Q, Li Y . LncRNA DUXAP8 induces breast cancer radioresistance by modulating the PI3K/AKT/mTOR pathway and the EZH2-E-cadherin/RHOB pathway. Cancer Biol Ther. 2022; 23(1):1-13. PMC: 9635553. DOI: 10.1080/15384047.2022.2132008. View

20.

Ma J, Zhao W, Zhang H, Chu Z, Liu H, Fang X . Long non-coding RNA ANRIL promotes chemoresistance in triple-negative breast cancer via enhancing aerobic glycolysis. Life Sci. 2022; 306:120810. DOI: 10.1016/j.lfs.2022.120810. View